NCT06436534View on ClinicalTrials.gov

Efficacy and Safety of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis

NARecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 24, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

May 31, 2026

Conditions
Rhinitis, Allergic
Interventions
DRUG

Ganciclovir Oral Capsule

2-week treatment phase：Ganciclovir capsules(250mg), take 2 capsules twice a day

DRUG

Ganciclovir Simulant Oral Capsule

2-week treatment phase：Ganciclovir simulant capsules(0mg), take 2 capsules twice a day

DRUG

Mometasone Nasal

From screening phase to follow-up phase：Mometasone furoate aqueous nasal spray(50μg/spray), take 1 spray once a day

Trial Locations (1)

430022

RECRUITING

Wuhan Union Hospital, Wuhan

All Listed Sponsors
lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER